Market Research report comprising epidemiology data, FDA approvals & patent expirations, market dynamics (drivers, unmet needs, barriers) along with market size and forecast of current marketed drugs and Phase 3 & NDA-filed pipeline drugs. This report also covers geographic (regional) market segmentation, market share of key players, mapping of pipeline (Preclinical to Phase 3) and profiling of major companies in this market.

1. Anti-Convulsants Market - Global Marketed and Pipeline
Drugs Analysis and Forecast - 2015 to 2025
http://www.xcelsioranalytics.com
info@xcelsioranalytics.com
Table of Contents and Report Description
Anti-Convulsants market, comprising epidemiology data, FDA approvals & patent expirations,
market dynamics (drivers, unmet needs, barriers) along with market size and forecast of current
marketed drugs and Phase 3 & NDA-filed pipeline drugs. This report also covers geographic
(regional) market segmentation, market share of key players, mapping of pipeline (Preclinical to
Phase 3) and profiling of major companies in this market.
Section Description
Section 1:
Introduction Board
An interactive interface for graphical and tabular destination to any
section of the Anti-Convulsants market report.
Section 2:
Epidemiology
Qualitative analysis of the epidemiology data (causes, signs,
symptoms and currently available treatments) for Anti-Convulsants
along with worldwide prevalence data of major indications treated by
Anti-Convulsants (forecasted till 2025).
Section 3:
FDA Approvals and
Patent Expirations
Tabular representation of all the FDA approvals and expected patent
expirations of marketed Anti-Convulsants along with expected FDA
approval dates of Phase 3 and NDA-filed pipeline Anti-Convulsants.
Section 4:
Market Dynamics
and Principal
Unmet Needs
Description of principal unmet needs in the Anti-Convulsants market
coupled with the top indicators that are driving and restraining the
market growth.

2. Section 5:
Market Size and
Forecast – Total
Drugs and
Marketed Drugs
 Quantitative Analysis of total drugs market and top marketed
Anti-Convulsants (estimated market size and forecast in USD
million) for the period 2015 to 2025.
 Qualitative Analysis (patent expiry effects, influence of pipeline
drugs, patient and physician preference) for the current marketed
drugs in the Anti-Convulsants market.
Section 6:
Market Size and
Forecast - Phase 3
and NDA-filed
Pipeline Drugs
 Quantitative Analysis of Phase 3 and NDA-filed pipeline Anti-
Convulsants (estimated market size and forecast in USD million)
for the period 2015 to 2025.
 Qualitative Analysis of Phase 3 and NDA-filed pipeline drugs
(expected physician prescribing pattern and patient preference,
competition with current marketed drugs) for the Anti-
Convulsants market.
Section 7:
Market Size and
Forecast – Market
by Major
Indications
Quantitative and qualitative analysis of major indications treated by
Anti-Convulsants (estimated market size and forecast in USD
million) for the period 2015 to 2025.
Section 8:
Market Size and
Forecast - Marketed
Drugs by
Geographic Regions
Quantitative and qualitative analysis of marketed drugs in the Anti-
Convulsants market (estimated market size and forecast in USD
million) by geographic regions for the period 2015 to 2025.
 Developed Regions (North America and Europe)
 Developing Regions (Asia-Pacific, Latin America and
Middle-East)
 Rest of the World (RoW)
Section 9:
Market Share
Analysis - Key
Players (2015 and
2025)
% value market share estimated and analyzed for top players of the
Anti-Convulsants market for the year 2015 and forecasted for the
year 2025.

3. Section 10:
Pipeline Analysis
Pipeline Analysis for the Anti-Convulsants market:
 Phases Mapped:
 Discovery and Preclinical Phase
 Clinical Phase 1
 Clinical Phase 2
 Clinical Phase 3
 Data Points Covered:
 Number of pipeline in each phase
 Number of “new or first-in-class” molecules, “me-too” drugs
and “generic” drugs
 Number of companies and their comparative analysis
Section 11:
Company Profiles
Top 5 companies (current marketed drugs) and Top 3 Companies
(pipeline drugs) in the Anti-Convulsants market profiled with
following parameters (tabular representation):
 Financials (total revenue and specific market revenues)
 Business Overview
 Product Review
 Major Consolidations (mergers and acquisitions, joint ventures,
partnerships and collaborations)
Section 12:
Sources and
Methodology
Tabular representation of principal secondary and primary sources
utilized and description of the detailed methodology and assumptions
adopted while estimating the Anti-Convulsants market.